AltruBio is a biopharma company developing new antibody therapeutics for the treatment of immunological diseases.
AltruBio has introduced an antibody that targets a novel regulator of the immune system to precisely remove chronically over-activated T-cells partly responsible for causing autoimmune disease.
AltruBio's approach balances the benefit of precisely targeting the immune system to reduce autoimmune diseases with avoiding overcorrecting the immune system. The method has displayed proof of mechanism in four autoimmune and inflammatory diseases.
AltruBio's pipeline includes programs aimed at combatting acute Graft Versus Host Disease, and Ulcerative Colitis.
AltruBio has introduced an antibody that targets a novel regulator of the immune system to precisely remove chronically over-activated T-cells partly responsible for causing autoimmune disease.
AltruBio's approach balances the benefit of precisely targeting the immune system to reduce autoimmune diseases with avoiding overcorrecting the immune system. The method has displayed proof of mechanism in four autoimmune and inflammatory diseases.
AltruBio's pipeline includes programs aimed at combatting acute Graft Versus Host Disease, and Ulcerative Colitis.
Total raised: $288M
Investors 2
| Date | Name | Website |
| 20.01.2022 | aMoon Fund | amoon.fund... |
| - | EVX Ventur... | evx.ventur... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.05.2024 | Series B | $225M | - |
| 19.04.2021 | Series A | $63M | aMoon Fund |
Mentions in press and media 9
| Date | Title | Description |
| 24.05.2024 | The Week’s 10 Biggest Funding Rounds: Scale AI’s Massive $1B Deal Leads Slower Week | 9 Shares Email Facebook Twitter LinkedIn Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board. This is a w... |
| 21.05.2024 | AltruBio Secures Up To $225M Series B Financing | AltruBio, a San Francisco, CA-based clinical stage biotechnology company, raised up to $225M in Series B funding. The round was led by BVF Partners LP, with participation from new investors RA Capital Management, Cormorant Asset Management,... |
| 21.05.2024 | AltruBio, after tweaking checkpoint drug, raises $225M for midphase ulcerative colitis program | AltruBio has roared back after another pivot in its twisty history, securing up to $225 million in series B funding to take an immune checkpoint enhancer through a midphase ulcerative colitis program. San Francisco-based AltruBio hit reset ... |
| 21.05.2024 | AltruBio Raises $225M Oversubscribed Series B | SAN FRANCISCO, CA, AltruBio today announced an oversubscribed Series B financing of up to $225 million. >> Click here for more funding data on AltruBio >> To export AltruBio funding data to PDF and Excel, click here AltruBio, a... |
| 16.04.2021 | AltruBio snags $63M Series A | AltruBio has raised $63 million in a round led by aMoon. The clinical-stage biotech company is developing antibody therapeutics and other treatments for autoimmune and inflammatory diseases. AltruBio is based in the San Francisco area. Addi... |
| 15.04.2021 | New name, new board, new focus: AltruBio relaunches with $63M series A | - |
| 15.04.2021 | AltruBio Raises $63 Million Series A Round To Continue Its Company Transformation | REDWOOD CITY, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company, has announced the completion of a $63 million Series A financing round. The round was led by aMoon with ... |
| 15.04.2021 | AltruBio Scores $63M Series A Funding | REDWOOD CITY, CA, AltruBio announced the completion of a $63 million Series A financing round led by aMoon. >> Click here for more funding data on AltruBio >> To export AltruBio funding data to PDF and Excel, click here A... |
| - | AltruBio | “AltruBio fulfills unmet medical needs by creating antibody-targeted therapy. Science, passion and a global vision make it possible. Learn more about how we are improving patients’ lives.” |